Aim To explore the way people living with HIV and healthcare providers in Togo judge the priority of HIV-infected patients regarding the allocation of antiretroviral drugs.
Method From June to September 2015, 200 adults living with HIV and 121 healthcare providers living in Togo were recruited for the study. They were presented with stories of a few lines depicting the situation of an HIV-infected patient and were instructed to judge the extent to which the patient should be given priority for antiretroviral drugs. The stories were composed by systematically varying the levels of four factors: (a) the severity of HIV infection, (b) the financial situation of the patient, (c) the patient's family responsibilities and (d) the time elapsed since the first consultation.
Results Five clusters were identified: 65% of the participants expressed the view that patients who are poor and severely sick should be treated as a priority, 13% prioritised treatment of patients who are poor and parents of small children, 12% expressed the view that the poor should be treated as a priority, 4% preferred that the sickest be treated as a priority and 6% wanted all patients to get treatment.
Conclusions WHO's guideline regarding antiretroviral therapy allocation (the sickest first as the sole criterion) currently in use in many African countries does not reflect the preferences of Togolese people living with HIV. For most HIV-infected patients in Togo, patients who cannot get treatment on their own should be treated as a priority.
- Allocation of Health Care Resources
- Patient perspective
- Demographic Surveys/Attitudes
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors LK, PCS and EM designed the study and research material, conducted the statistical analyses and contributed to interpretation of the data. LK supervised the data collection, devised the paper and wrote the first draft. All authors contributed to subsequent drafts and approved the final version of the manuscript.
Funding This study was funded by a grant from Canada Research Chairs programme awarded to LK. Grant number: #950-230745.
Disclaimer The funding body had no role in the study or the decision to submit the paper for publication.
Competing interests None declared.
Patient consent Obtained.
Ethics approval The Institutional Review Board of the University of Québec (TELUQ).
Provenance and peer review Not commissioned; externally peer reviewed.
Read the full text or download the PDF:
Other content recommended for you
- Comparison of the therapeutic dose of warfarin in HIV-infected and HIV-uninfected patients: a study of clinical practice
- Gastrointestinal complications of HIV infection: changing priorities in the HAART era
- AIDS and the lung in a changing world
- Impairment of the intestinal barrier is evident in untreated but absent in suppressively treated HIV-infected patients
- Evaluating the reactivation of herpesviruses and inflammation as cardiovascular and cerebrovascular risk factors in antiretroviral therapy initiators in an African HIV-infected population (RHICCA): a protocol for a longitudinal cohort study
- Survival of HIV-infected patients in the intensive care unit in the era of highly active antiretroviral therapy
- Immunological failure in HIV-infected adults from 2003 to 2015 in Southwest Ethiopia: a retrospective cohort study
- Survival outcomes of primary cutaneous T-cell lymphoma in HIV-infected patients: a national population-based study
- Clinical outcome of long-term survivors of progressive multifocal leukoencephalopathy
- Human gammaherpesviruses viraemia in HIV infected patients